Monica Carpenedo
University of Milan
ImmunologyRomiplostimAnticoagulantMedicineImmune system
What is this?
Publications 43
#1F. Zaja (DSM)
#2Monica CarpenedoH-Index: 9
Last. Potito Rosario Scalzulli (Casa Sollievo della Sofferenza)H-Index: 17
view all 11 authors...
Abstract Thrombopoietin receptor agonists (TPO-RAs) are currently indicated for continuous treatment of chronic primary immune thrombocytopenia (ITP). However, there is growing evidence that TPO-RAs can also trigger sustained response in 10–30% of cases after treatment tapering and discontinuation. Therefore, at least for selected responding patients, it might be rational to plan TPO-RA interruption to exploit off-treatment response. Intriguingly, complete or partial responses with TPO-RAs are f...
#2Laura RussoH-Index: 16
Last. Alessandro Rambaldi (University of Milan)H-Index: 87
view all 15 authors...
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a life-threatening immune-mediated thrombotic microangiopathy. Daily therapeutic plasma exchange (TPE) and the optimized use of rituximab have strikingly improved the outcome of this disease, however the rate of disease recurrence remains high. Specific predictors of relapse in patients in remission can be relevant for an optimal patient management. In this study, we aimed to identify predictive variables of disease relapse in a multi...
#1Bianca Rocca (UCSC: Catholic University of the Sacred Heart)H-Index: 35
#2Alberto TosettoH-Index: 42
Last. Alessandra IurloH-Index: 22
view all 32 authors...
Essential thrombocythemia (ET) is characterized by abnormal megakaryopoiesis and enhanced thrombotic risk. Once-daily (od), low-dose aspirin is the recommended antithrombotic regimen, but accelerated platelet generation may reduce the duration of platelet cyclooxygenase (COX)-1 inhibition. We performed a multicenter, double-blind trial to investigate the efficacy of three aspirin regimens in optimizing platelet COX-1 inhibition while preserving COX-2-dependent vascular thromboresistance. Two-hun...
2 CitationsSource
#1Francesca PalandriH-Index: 29
#2Cristina Santoro (Policlinico Umberto I)H-Index: 2
Last. Nicola VianelliH-Index: 37
view all 23 authors...
Abstract Introduction Primary Immune thrombocytopenia (ITP) in the elderly is a major clinical challenge which is increasingly frequent due to global ageing population. Materials and methods To describe baseline ITP features, management, and outcome, a centralized electronic database was established, including data of 451 patients aged ≥60 years that were treated from 2000 onwards and were observed for ≥1 year (total observation of 2704 patient-years). Results At ITP diagnosis, median age was 71...
1 CitationsSource
#2Laura RussoH-Index: 16
Last. Anna FalangaH-Index: 46
view all 16 authors...
#2Giuseppe AvvisatiH-Index: 46
Last. Sergio SiragusaH-Index: 31
view all 20 authors...
#1Elisa LucchiniH-Index: 2
#2Francesca PalandriH-Index: 29
Last. Francesco ZajaH-Index: 50
view all 22 authors...
#2G. SacculloH-Index: 3
Last. Giuseppe TagarielloH-Index: 17
view all 23 authors...
4 CitationsSource
#1Bruno Fattizzo (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 9
#2Raffaella Pasquale (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 1
Last. Wilma Barcellini (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 24
view all 14 authors...
It is well established that immune thrombocytopenia (ITP) results from increased immune mediated platelet destruction (anti-platelets antibodies, autoreactive T cells, and reduction of regulatory T cells) along with impaired production in the bone marrow.[1][1] The latter has been attributed to both
1 CitationsSource
#2Laura RussoH-Index: 16
Last. Anna FalangaH-Index: 46
view all 15 authors...